The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
Panattoni LE.
J Health Econ. 30(1):126-45. doi: 10.1016/j.jhealeco.2010.09.004. Epub 2010 Oct 8.
2011-01-01
Abstract
This purpose of this paper is to investigate the impact of Paragraph IV patent infringement decisions on brand drug pharmaceutical firms. Paragraph IV decisions determine whether a generic firm can enter before the period of exclusivity ends.
I construct a novel dataset of all Paragraph IV decisions and find that they disproportionately involve the highest revenue drugs, significant periods of patent protection, and a non-trivial portion of all brand drugs facing generic entry.
I also estimate the impact of Paragraph IV decisions on brand firm profitability and find they have large value consequences.
Research topics
Related publications
View all publications- Tai-Seale M, Olson CW, Li J, Chan AS, Morikawa C, Durbin M, Wang W, Luft HS.Health Aff. 36:655-662; doi:10.1377/hlthaff.2016.0811.2017 Apr 01
- McClellan SR, Casalino LP, Shortell SM, Rittenhouse DR.J Am Med Inform Assoc. 20(e1):e26-32. doi: 10.1136/amiajnl-2012-001271. Epub 2013 Feb 8.2013 Jun 01
- Francis L, Vorwaller MA, Aboumatar H, Frosch DL, Halamka J, Rozenblum R, Rubin E, Lee BS, Sugarman J, Turner K, Brown SM; Privacy, Access, and Engagement Task Force of the Libretto Consortium of the Gordon and Betty Moore Foundation.Crit Care Med. [Epub ahead of print]2016 Dec 02
- Stults CD, Baskin AS, Bundorf MK, Tai-Seale M.J Patient Experience. https://doi.org/10.1177/23743735177394132017 Nov 21
- Chung S, Lesser LI, Lauderdale DS, Johns NE, Palaniappan LP, Luft HS.Health Aff (Millwood). 34(1):11-20. doi: 10.1377/hlthaff.2014.0483.2015 Jan 01